Advertisement

Treatment of Acyclovir-Resistant Herpes Simplex and Varicella Zoster Virus Infections

  • Sharon Safrin
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 394)

Abstract

Acyclovir-resistant HSV (ACV-R-HSV) infections were first described in 1982.1 To date, over 100 patients with ACV-R-HSV infection have been identified. Although in vitro resis10 tance to acyclovir has been demonstrated in isolates recovered from immunocompetent hosts,2 for practical purposes only the severely immunocompromised patient develops clinically significant ACV-R-HSV (e.g. patients with AIDS, hematologic malignancies, congenital immune deficiencies, or those who have undergone organ transplantation3–9). The single exception to date is a report by Kost et al. of an HIV-negative immunocompetent man with increasingly frequent recurrences of genital HSV despite the use of maximal doses of oral acyclovir for suppression or for treatment.10 This patient, however, appeared to have acquired ACV-R-HSV infection through direct transmission, having had in the recent past 3 new sexual partners of whom 2 had HIV infection.

Keywords

Herpes Simplex Virus Acquire Immunodeficiency Syndrome Herpes Simplex Virus Infection Oral Acyclovir Acyclovir Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sibrack CD, Gutman LT, Wilfert CM, McLaren C, St.Clair MIR, Keller PM, Barry DW. Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. J Infect Dis 1982; 146: 673–682.PubMedCrossRefGoogle Scholar
  2. 2.
    McLaren C, Corey L, Dekket C, et al. In vitro sensitivity to acyclovir in genital herpes simplex viruses from acyclovir-treated patients. J Infect Dis 1983; 148: 868–875.PubMedCrossRefGoogle Scholar
  3. 3.
    Erlich KS, Mills J, Chatis P, Mertz GJ, Busch DF, Follansbee SE, Grant RM, Crumpacker CS. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989; 320: 293–296.PubMedCrossRefGoogle Scholar
  4. 4.
    Chatis PA, Miller CH, Schrager LE, Crumpacker CS. Successful treatment with foscarnet of an acyclovirresistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. N Engl J Med 1982; 320: 297–300.CrossRefGoogle Scholar
  5. 5.
    Safrin S, Assaykeen T, Follansbee S, Mills J. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. J Infect Dis 1990; 161: 1078–1084.PubMedCrossRefGoogle Scholar
  6. 6.
    Safrin S, Crumpacker C, Chatis P, Davis R, Hafner R, Rush J, Kessler HA, Landry B, Mills J, other members of the AIDS Clinical Trials Group.. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 1991; 325: 551–555.PubMedCrossRefGoogle Scholar
  7. 7.
    Vinckier F, Boogaerts M, De Clerck D, De Clercq E. Chronic herpetic infection in an immunocompromised patient: report of a case. J Oral Maxillofac Surg 1987; 45: 723–728.PubMedCrossRefGoogle Scholar
  8. 8.
    Ljungman P, Ellis MN, Hackman RC, Shepp DH, Meyers JD. Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. J Infect Dis 1990; 162: 244–248.PubMedCrossRefGoogle Scholar
  9. 9.
    Sacks SL, Wanklin RJ, Reece DE, Hicks KA, Tyler KL, Coen DM. Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity. Ann Intern Med 1989; 111: 893–899.PubMedCrossRefGoogle Scholar
  10. 10.
    Kost RG, Hill EL, Tigges M, Straus SE. Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient. N Engl J Med 1993; 329: 1777–1782.PubMedCrossRefGoogle Scholar
  11. 11.
    _ Norris SA, Kessler HA, Fife KH. Severe progressive herpetic whitlow caused by an acyclovir-resistant virus in a patient with AIDS. J Infect Dis 1987; 157: 209–210.CrossRefGoogle Scholar
  12. 12.
    Gateley A, Gander RM, Johnson PC, Kit S, Otsuka H, Kohl S. Herpes simplex virus 2 meningoencephalitis resistant to acyclovir in a patient with AIDS. J Infect Dis 1990; 161: 711 - I15.PubMedCrossRefGoogle Scholar
  13. 13.
    Pahwa S, Biron K, Lim W, Swenson P, Kaplan MH, Sadick N, Pahwa R. Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. JAMA 1988; 260: 2879–2882.PubMedCrossRefGoogle Scholar
  14. 14.
    Jacobson MA, Berger TG, Fikrig S, Becherer P, Moohr SW, Stanat SC, Biron K.K. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS)_ Ann Intern Med 1990; 112: 187–191.PubMedGoogle Scholar
  15. 15.
    Safrin S, Berger TG, Gilson I, Wolfe PR, Wofsy CB, Mills J, Biron KK. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med 1991: 115: 19–21.PubMedCrossRefGoogle Scholar
  16. 16.
    Linnemann CC, Biron KK, Hoppenjans WG, Solinger AM. Emergence of acyclovir-resistant varicella zoster virus in an AIDS patient on prolonged acyclovir therapy. AIDS 1990; 4:577–579_Google Scholar
  17. 17.
    Janier M, Billion B, Baccard M, Morinet F, Scieux C, Peron Y, Civatte J. Chronic varicella zoster infection in acquired immunodeficiency syndrome. J Am Acad Dermatol 1988; 18: 584–585.PubMedCrossRefGoogle Scholar
  18. 18.
    Leport C, Puget S, Pepin JM, Levy S, Perronne C, Brun-Vezinet F, Vilde JL. Meningoradiculoneuritis due to acyclovir-resistant varicella-zoster virus in a patient with AIDS. J Infect Dis 1993; 168: 1330–1.CrossRefGoogle Scholar
  19. 19.
    Balfour HH. Resistance of herpes simplex to acyclovir. Ann Intern Med 1983; 98: 404–406.PubMedCrossRefGoogle Scholar
  20. 20.
    Siegal FP, Lopez C, Hammer GS, Brown AE, Kornfeld SJ, Gold J, Bassett J, Hirschman SZ. Cunningham-Rundles C, Adelsberg BR, Parham DM, Siegal M, Cunningham-Rundles S. Armstrong D. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med 1981; 305: 1439–1444.PubMedCrossRefGoogle Scholar
  21. 21.
    Erlich KS, Jacobson MA, Koehler JE, Follansbee SE, Drennan DP, Gooze L. Safrin S. Mills J. Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS): an uncontrolled trial. Ann Intern Med 1989. 110: 710–713.PubMedCrossRefGoogle Scholar
  22. _ Heidelberger C. On the molecular mechanism of the antiviral activity of trifluorothymidine_ Ann NY Acad Sci 1974; 317–324.Google Scholar
  23. 23.
    Field H, McMillan A, Darby G. The sensitivity of acyciovir-resistant mutants of herpes simplex virus to other antiviral drugs. J Infect Dis 1981; 143: 281–285.PubMedCrossRefGoogle Scholar
  24. 24.
    Murphy M, Morley A, Eglin RP, Monteiro E. Topical trifluridine for mucocutaneous acyclovir-resistant herpes simplex II in AIDS patient. Lancet 1992; 340:1040_Google Scholar
  25. 25.
    Birch CI, Tyssen DP, Tachedjian G, Doherty R, Hayes K, Mijch A, Lucas CR. Clinical effects and in vitro studies of trifluorothymidine combined with interferon-a for treatment of drug-resistant and–sensitive herpes simplex virus infections. J Infect Dis 1992; 166: 108–112.PubMedCrossRefGoogle Scholar
  26. 26.
    Kessler HA, Weaver D, Benson CA, Pottage JC, Safrin S, Nevin T, Davis R, Owens S, Korvick J. ACTG 172: treatment of acyclovir-resistant (ACV-R) mucocutaneous herpes simplex virus (HSV) infection in patients with AIDS: open label pilot study of topical trifluridine (TFT). Infectious Diseases Society of America 1992; Abstract 82:Anaheim, CA.Google Scholar
  27. 27.
    Fletcher CV, Englund JA, Bean B, Chinnock B, Brundage DM, Balfour HH. Continous infusion of high-dose acyclovir for serious herpesvirus infections. Antimicrob Agents Chemother 1989; 33: 1375–1378.PubMedCrossRefGoogle Scholar
  28. 28.
    Engel JP, Englund JA, Fletcher CV, Hill EL. Treatment of resistant herpes simplex virus with continuous-infusion acyclovir. JAMA 1990; 263: 1662–1664.PubMedCrossRefGoogle Scholar
  29. 29.
    Spector T, Harrington JA, Morrison Jr RW, Lambe CU, Nelson DJ, Averett DR, Biron K, Furman PA. 2acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (A1110U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella-zoster viruses and a potentiator of acyclovir. Proc Natl Acad Sci USA 1989; 86: 1051–1055.PubMedCrossRefGoogle Scholar
  30. 30.
    Lobe DC, Spector T, Ellis MN. Synergistic topical therapy by acyclovir and All10U for herpes simplex virus induced zosteriform rash in mice. Antiviral Res 1991; 15: 87–100.PubMedCrossRefGoogle Scholar
  31. 31.
    Spector T, Lobe DC, Ellis MN et al. Inactivators of herpes simplex virus ribonucleotide reductase: hematological profiles and in vivo potentiation of the antiviral activity of acyclovir. Antimicrob Ag Chemother 1992; 36: 934–937CrossRefGoogle Scholar
  32. 32.
    Safrin S, Schacker T, Delehanty J, Hill E, Corey L. Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir. Antimicrob Agents Chemother 1993; 37: 975–979.PubMedCrossRefGoogle Scholar
  33. 33.
    Barnard DL, Smee DF, Huggman JH et al. Antiherpesvirus activity and mode of action of SP-303, a novel plant flavonoid. Chemotherapy 1993; 39: 203–211PubMedCrossRefGoogle Scholar
  34. 34.
    Safrin S, McKinley G, McKeough M et al. Treatment of acyclovir-unresponsive cutaneous herpes simplex virus infection with topically applied SP-303. Antiviral Res 1994; 25: 185–192.PubMedCrossRefGoogle Scholar
  35. 35.
    a. Hardy WD. Foscarnet treatment of acyclovir-resistant herpes simplex virus infection inpatients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen- comparative trial. Amer J Med 1992; 92 (suppl 2A): 30S - 35S.PubMedCrossRefGoogle Scholar
  36. 36.
    Safrin S, Kemmerly S, Plotkin B, Smith T, Weissbach N, De Veranez D, Phan LD. Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J Infect Dis 1994; 169: 193–196.PubMedCrossRefGoogle Scholar
  37. 37.
    DeClerq E. Virus drug resistance: thymidine kinase-deficient mutants of herpes simplex virus. Therapeutic approaches. Ann 1st Super Sanìta 1987; 23: 841–848.Google Scholar
  38. 38.
    Lalezari JP, Drew WL, Glutzer E, Miner D, Safrin S, Owen Jr WF, Davidson JM, Fisher PE, Jaffe HS. Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovirresistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. J Infect Dis 1994; 170: 570–2.PubMedCrossRefGoogle Scholar
  39. 39.
    Snoeck R, Andrei G, Gerard M, Silverman A. Hedderman A, Balzarini J, Sadzot-Delvaux C, Tricot G, Clumeck N, De Clercq E. Successful treatment of progressive mucocutaneous infection due to acyclovirand foscarnet-resistant herpes simplex virus with (S)-l-(3-hydroxy-2phosphonylmethoxypropyl)cytosine(HPMPC). Clin Infect Dis 1994; 18: 570–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Sacks SL, Portnoy J, Lawee D, et al. Clinical course of recurrent genital herpes and treatment with foscarnet cream: results of a Canadian multicenter trial. J Infect Dis 1987; 155: 178–186PubMedCrossRefGoogle Scholar
  41. 41.
    Barton SE, Munday PE, Kinghorn GR et al. Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled multicentre study. Genitourin Med 1986; 62: 247–250PubMedGoogle Scholar
  42. 42.
    Oberg B. Antiviral effects of phosphonoformate. Pharmac Ther 1983; 19: 387–415CrossRefGoogle Scholar
  43. 43.
    De Clerq E, Sakuma T, Baba M, et al. Antiviral activity of phosphonomehoxyalkyl derivatives of purine and pyrimidines. Antiviral Res 198; 8: 261–272Google Scholar
  44. 44.
    Balfour H, Benson C, Bruan J et al. Managment of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J Acq Immune Defic Syndr 1994; 7: 254–260.Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Sharon Safrin

There are no affiliations available

Personalised recommendations